Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study

Inclusion Criteria: * Age equal or more than 18 years * Chest pain \> 20 minutes * Primary PCI \<24h from symptoms onset * ST-segment elevation of \> 1 mm in \> 2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \> 1 mm in \> 2 contiguous anterior leads * Presence of at least one acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery from 2.5-4.0 mm in diameter that can be covered with one or multiple stents * Signed informed consent Exclusion Criteria: * Female of childbearing potential (age \< 50 and last menstruation within the last 12 months), who did not underwent tubal ligation, ovariectomy or hysterectomy * Known intolerance to aspirin, clopidogrel, heparin, bivalirudin, cobalt, chromium, nickel, sirolimus or contrast material * Currently participating in another trial before reaching primary endpoint * Mechanical complication of acute myocardial infarction (e.g. cardiogenic shock…) * Acute myocardial infarction secondary to stent thrombosis * Previously stented infarction related artery (IRA) * Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period * Patients with non-cardiac comorbid conditions with life expectancy\< 1 year or that may result in protocol non-compliance * History of bleeding diathesis or known coagulopathy * Use of oral anticoagulants